Assessing the Utility, Impact, and Adoption Challenges of an Artificial Intelligence-Enabled Prescription Advisory Tool for Type 2 Diabetes Management: Qualitative Study.

BACKGROUND: The clinical management of type 2 diabetes mellitus (T2DM) presents a significant challenge due to the constantly evolving clinical practice guidelines and growing array of drug classes available. Evidence suggests that artificial intelligence (AI)-enabled clinical decision support systems (CDSSs) have proven to be effective in assisting clinicians with informed decision-making. Despite the merits of AI-driven CDSSs, a significant research gap exists concerning the early-stage implementation and adoption of AI-enabled CDSSs in T2DM management. OBJECTIVE: This study aimed to explore the perspectives of clinicians on the use and impact of the AI-enabled Prescription Advisory (APA) tool, developed using a multi-institution diabetes registry and implemented in specialist endocrinology clinics, and the challenges to its adoption and application. METHODS: We conducted focus group discussions using a semistructured interview guide with purposively selected endocrinologists from a tertiary hospital. The focus group discussions were audio-recorded and transcribed verbatim. Data were thematically analyzed. RESULTS: A total of 13 clinicians participated in 4 focus group discussions. Our findings suggest that the APA tool offered several useful features to assist clinicians in effectively managing T2DM. Specifically, clinicians viewed the AI-generated medication alterations as a good knowledge resource in supporting the clinician's decision-making on drug modifications at the point of care, particularly for patients with comorbidities. The complication risk prediction was seen as positively impacting patient care by facilitating early doctor-patient communication and initiating prompt clinical responses. However, the interpretability of the risk scores, concerns about overreliance and automation bias, and issues surrounding accountability and liability hindered the adoption of the APA tool in clinical practice. CONCLUSIONS: Although the APA tool holds great potential as a valuable resource for improving patient care, further efforts are required to address clinicians' concerns and improve the tool's acceptance and applicability in relevant contexts.

Fulminant type 1 diabetes, an underrecognized and unique subtype of type 1 diabetes: A case series from Singapore.

Fulminant type 1 diabetes (FT1D) is a unique subtype of type 1 diabetes, characterized by acute absolute insulin deficiency, severe ketosis, and increased risk of hypoglycemia, glycemic variability and microvascular complications. Seven people with FT1D were identified from two tertiary centers in Singapore. Six were Chinese, the mean age was 35 years and all were lean (mean body mass index 20.3 kg/m2). All presented with diabetes ketosis or ketoacidosis and low C-peptide. All but one had low glutamic acid decarboxylase antibodies. Nearly half had a missed/delayed diagnosis of FT1D. Three had frequent hypoglycemia, which improved after transition to continuous subcutaneous insulin infusion therapy. Individuals with FT1D experience unique diagnostic and management challenges associated with rapid absolute insulin deficiency. Greater awareness about this clinical entity is required.

Acute Flaccid Tetraparesis after COVID-19 Infection: Think of the Thyroid.

A previously well 32-year-old Chinese male presented with acute bilateral upper and lower limb paralysis upon waking, ten days after the onset of COVID-19 infection. Examination revealed areflexia over all four limbs, associated with reduced muscle strength, but no sensory or cranial nerve deficit. Initial concern was Guillain-Barre syndrome given the acute flaccid paralysis following COVID-19 infection. However, investigations revealed severe hypokalaemia (1.7 mmol/L) and primary hyperthyroidism. He was treated for thyrotoxic periodic paralysis (TPP) with ß-blockers, antithyroid medications, and intravenous potassium chloride (KCl). Despite frequent monitoring of potassium, rebound hyperkalaemia occurred with prompt resolution of paralysis.

Compliance With Asthma Guidelines and Association With Outcomes in the Emergency Department of a Tertiary Care Teaching Hospital.

BACKGROUND: Despite the existence of guidelines for treating acute asthma patients in the emergency department (ED), compliance is often poor. We aimed to examine the compliance to treatment guidelines for asthma at our tertiary care teaching hospital's ED and association with re-attendance rates. METHODS: We performed a retrospective analysis of electronic patient records of patients above 16 years old who presented to our ED with a primary diagnosis of asthma over a 6 month period in 2012. Patient demographics such as age, gender, history of previous intubations and hospitalisations were reviewed, as were the treatment administered during the ED visit and on discharge. Concordance of treatment was compared with the National Asthma Education and Prevention Program's Expert Panel Report 3 (NAEPP EPR3) guidelines. Re-attendance rates to our ED within one year were then analysed. RESULTS: A total of 552 patients were included in the study. We found that 151 (27.4%) of patients reattended within the year, 35 (6.3%) returned more than twice. Low compliance to the EPR3 guidelines (p = 0.005), age of between 41 and 60 (p = 0.049), previous hospitalisations for asthma (p < 0.001) and non-use of recommended systemic corticosteroids (p = 0.020) in the ED predicted a higher re-attendance rate. Follow up care and medications on discharge were not signifi cant factors. CONCLUSION: Low compliance to recommended treatment by established guidelines is associated with higher re-attendance, as are middle age and previous hospitalisations. Besides managing pressures of time and resource limitations in the ED, an increased awareness of guidelines amongst doctors will improve asthma care.